Hostname: page-component-6d856f89d9-5pczc Total loading time: 0 Render date: 2024-07-16T06:18:30.682Z Has data issue: false hasContentIssue false

Comprehensive mutation analysis of TSC1 using two-dimensional DNA electrophoresis with DGGE

Published online by Cambridge University Press:  01 November 1998

S. L. DABORA
Affiliation:
Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115 Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115 Harvard Medical School, Boston, MA 02115
I. SIGALAS
Affiliation:
Molecular Genetics Section, Gerontology Division, Beth Israel Deaconess Medical Center, Boston MA 02115 Harvard Medical School, Boston, MA 02115
F. HALL
Affiliation:
Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115
C. ENG
Affiliation:
Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115 Harvard Medical School, Boston, MA 02115
J. VIJG
Affiliation:
Molecular Genetics Section, Gerontology Division, Beth Israel Deaconess Medical Center, Boston MA 02115 Harvard Medical School, Boston, MA 02115
D. J. KWIATKOWSKI
Affiliation:
Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115 Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115 Harvard Medical School, Boston, MA 02115
Get access

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterised by the development of benign tumors in multiple organs often causing serious neurologic impairment. To develop a reliable genetic test for TSC, two-dimensional electrophoresis with denaturing gradient gel electrophoresis (2D DGGE) has been developed to detect mutations in TSC1. The 23 exons of TSC1 were amplified using two rounds of PCR. In the first round, all coding regions of TSC1 were amplified in four fragments ranging in size from 7.4 kb to 9.9 kb. In the second round, 32 fragments representing 23 exons were amplified using primers designed to avoid overlapping fragments and with a GC clamp on one end to optimise melting characteristics. These exon fragments were then separated by size in the first dimension using a polyacrylamide gel, and by melting characteristics in the second dimension using a urea/formamide gradient to yield 32 distinct bands. If a mutation is present, four bands instead of one, are typically observed. During the development of this assay, we analysed 63 patient samples with known TSC1 mutations from prior studies. These 63 patients had 68 known mutations or polymorphisms. With DGGE, all 68 of these were identified (45 point mutations, 3 small insertions, 20 small deletions) and an additional 27 single base variants were discovered. To evaluate the assay, we analysed 19 of these samples in a blinded study. In the blinded analysis, 19/20 (95%) known mutations or polymorphisms were detected. The single missed mutation in the blinded analysis could be identified in retrospect and the assay was modified accordingly. During this study, we identified 2 new mutations (exon 8 and exon 15), a new polymorphism (intron 4), and the first variant identified in a non-coding exon (exon 2).

Type
Research Article
Copyright
University College London 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)